<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60577">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02147535</url>
  </required_header>
  <id_info>
    <org_study_id>INDICES-WP2-2</org_study_id>
    <nct_id>NCT02147535</nct_id>
  </id_info>
  <brief_title>Impact of CES1 Genotype on Metabolism of Methylphenidate</brief_title>
  <official_title>Impact of CES1 Genotype on Metabolism of Methylphenidate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science, Innovation and Higher Education (Denmark)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mental Health Centre Sct. Hans (Denmark)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leiden Academic Center for Drug Research (LACDR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether differences in the gene coding for the
      liver enzyme carboxylesterase 1 (CES1) means differences in the metabolism of
      methylphenidate, a CES1 dependent drug.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Plasma concentration of methylphenidate and ritalinic acid</measure>
    <time_frame>Predose and 3 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>We are looking at the ratio of methylphenidate to ritalinic acid (metabolite) 3 hours post-dose as a measure of CES1 activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolomic Profile</measure>
    <time_frame>Predose/pre-meal, predose/post-meal and 3 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Three samples for each participant during the trials (as indicated above). Metabolomics will be assessed with focus on lipids (lipid platform) and with use of usual concentration measures (eg nanomolar (nM))</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Carboxylesterase 1 (CES1) Genotype</condition>
  <condition>CES1 Activity</condition>
  <arm_group>
    <arm_group_label>Methylphenidate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>10 mg as a single dose followed by one blood sample 3 hours post-dose</description>
    <arm_group_label>Methylphenidate</arm_group_label>
    <other_name>Ritalin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years old

          -  Caucasian

        Exclusion Criteria:

          -  Chronic disease (except hay fever and eczema)

          -  Pregnancy

          -  Smoking

          -  High level of alcohol consumption (&gt; 21 units per week for men and 14 for women)

          -  Known allergy towards methylphenidate

          -  Permanent use of medication (contraception ok)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Stage, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Bispebjerg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claus Stage, M.D.</last_name>
    <phone>+45 29112919</phone>
    <email>clausstage@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Bispebjerg University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>May 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Claus Stage</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
